North America Pulsed Field Ablation Market Outlook (2022-2033)

Rise of Atrial Fibrillation Rates

Atrial fibrillation (AFib) is increasingly a focal point of cardiovascular care in North America, driven by aging populations and shifting lifestyle factors. Clinicians are encountering more patients with irregular heart rhythms during routine wellness checks and cardiology referrals. Primary care physicians are more vigilant about screening for rhythm abnormalities, particularly among adults over 60, which has amplified the number of diagnoses entering electrophysiology pathways. Patients are also more informed about AFib risks, such as stroke and heart failure and are actively discussing therapeutic options with their care teams.

Lifestyle trends in North America, including a higher prevalence of obesity and metabolic syndrome, continue to shape the clinical landscape surrounding AFib. Individuals with sedentary work patterns, combined with diet‑related risk factors, are presenting with arrhythmia symptoms earlier than in past decades, prompting earlier intervention. Cardiologists are adapting to these shifts by recommending catheter‑based therapies sooner, especially in patients where medication alone offers limited symptom control.

As rates of AFib increase, there will be an increasing need for more sophisticated intervention procedures such as pulsed field ablation (PFA). Electrophysiologists at various top heart centers are beginning to include PFA in their range of services because of its promise of being selective when it comes to tissue and minimizing procedure-related risks. The variety of clinical settings from which these numbers emerge represents the active response of a North American market to AFib.

Modern Innovations in Pulsed Field Ablation

Pulsed field ablation technologies have seen fast progress in North America, where there has been a distinct trend towards developing highly precise devices. The first users of PFA devices were found in big cities such as New York, Toronto, and Los Angeles. They use these devices in their electrophysiology laboratories due to the clinicians’ desire for methods that will focus on the atrial tissues without affecting other parts of the body.

Modern systems for PFA provide more sophisticated catheter control, optimized energy delivery curves, and better real-time visualization capabilities. Physicians practicing cardiology in the US and Canada are using them in order to simplify the procedure of pulmonary vein isolation, which is essential for the procedure of AFib ablation. Combining PFA and cardiac mapping technology significantly helped physicians perform the procedure in a safe and reliable way. This innovation appeals greatly to physicians in North America due to its safety and reliability aspects.

Beyond hardware, software innovations, including lesion prediction algorithms and cloud‑based procedural analytics, are shaping how PFA is practiced in North America. Training and professional exchange through regional electrophysiology societies have accelerated adoption and helped clinicians refine techniques. As a result, pulsed field ablation is increasingly perceived not just as an alternative to thermal methods but as a core component of modern AFib care, reflecting the broader North American emphasis on innovation, evidence generation, and patient‑centric outcomes.

The "North America Pulsed Field Ablation Market Size and Forecast (2022–2033)" report provides a detailed analysis of the market covering below areas:

• North America Pulsed Field Ablation market size and forecast at regional and country levels for all market segments covered under the scope
• North America Pulsed Field Ablation market trends, as well as drivers, restraints, and opportunities
• North America Pulsed Field Ablation market analysis covering key trends, regional framework, major players, regulations, and recent developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the North America Pulsed Field Ablation market
• Detailed company profiles, including SWOT analysis

The geographical scope of the North America Pulsed Field Ablation market report is divided into: The US, Canada, and Mexico. The US held the largest share in 2025.

The US plays a dominant role in the development of the North American pulsed field ablation industry owing to its well-developed healthcare sector, high incidence of heart arrhythmias among the population, and prompt application of innovative medical devices. Pulsed field ablation technology, which implies non-thermal ablation without affecting surrounding tissues, is highly efficient in treating the condition compared to traditional thermal procedures, thus being especially relevant in terms of clinical effectiveness.

Clinics in the US implement advanced systems for diagnosing cardiac arrhythmia, as well as modern electrophysiology laboratories, ensuring efficient integration of the procedure within the treatment framework. In addition, there are many opportunities for acquiring additional professional skills and cooperation between medical practitioners and manufacturers of pulsed field devices. However, the relatively high cost of the procedure and uneven distribution of experts specializing in electrophysiology might present barriers to the use of the new technology in rural clinics. The leading role of the US in the implementation of pulsed field ablation can be explained by its innovative culture, efficient financing policies, and early adoption of innovative devices. The country is capable of setting the pace for the region as it creates benchmarks in terms of adopting the procedure.

• The report includes qualitative and quantitative data in the North America Pulsed Field Ablation market across product type, application, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the North America Pulsed Field Ablation market.
• Chapter 3 focuses on the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the North America Pulsed Field Ablation market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the North America Pulsed Field Ablation market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 10 cover North America Pulsed Field Ablation market segments by product type, application, end user, and geography across The United States, Canada and Mexico. They cover the market revenue, forecast, and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the North America Pulsed Field Ablation market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The North America pulsed field ablation market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the North America pulsed field ablation market are:

• In December 2025, Abbott Laboratories announced that the US Food and Drug Administration approved its Volt Pulsed Field Ablation System, expanding Abbott’s cardiac rhythm management portfolio and enabling the company to begin commercial use of the Volt PFA system in the United States.
• In October 2025, Kardium announced the first commercial procedures in the US using its Globe Pulsed Field System following recent FDA approval, representing a key product launch and clinical adoption step for its integrated PFA technology in the North American market.